Harvard Bioscience Reports Fourth Quarter and Year-End 2017 Results

Harvard Bioscience (Nasdaq:HBIO) a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported its financial results for the fourth quarter and full year ended December 31, 2017.

As quoted in the press release:

“With our third consecutive quarter of top line organic growth and our recent acquisition of Data Sciences International, we enter 2018 with enthusiasm for the year ahead,” said Jeffrey Duchemin, President and CEO of Harvard Bioscience.  “Our product lines in electrophysiology continued the trend from earlier quarters and produced solid results, remaining one of our most important competitive strengths.  The results we announced today stem from our commitment to and execution against our corporate strategy.  Full year 2017 ended with top line and operational results trending upward and we expect this to accelerate with the acquisition of Data Sciences International and the sale of Denville Scientific in the first quarter of 2018.  We are confident that the continuing transformation of Harvard Bioscience into a pure play life science instrumentation company, with a more innovative product portfolio and less reliance on academic research funding, will bode well for our company and generate accelerated top line and bottom line growth.”

Click here to read the full press release.